Wedbush Analysts Lift Earnings Estimates for argenex

argenex SE (NASDAQ:ARGX) – Wedbush lifted their Q4 2025 earnings per share estimates for argenex in a report released on Thursday, October 30th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $6.15 per share for the quarter, up from their previous estimate of $5.05. Wedbush currently has a “Outperform” rating and a $880.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex’s Q1 2026 earnings at $7.00 EPS, Q2 2026 earnings at $7.78 EPS, Q3 2026 earnings at $8.56 EPS, Q4 2026 earnings at $9.20 EPS, FY2026 earnings at $32.56 EPS, FY2027 earnings at $44.33 EPS and FY2028 earnings at $59.28 EPS.

Other research analysts have also issued research reports about the company. TD Cowen lifted their price target on argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Guggenheim restated a “buy” rating and set a $1,070.00 price objective on shares of argenex in a research report on Thursday, September 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $864.68.

argenex Stock Performance

Shares of ARGX opened at $831.48 on Monday. The stock has a 50 day moving average price of $774.59 and a 200 day moving average price of $658.12. The stock has a market capitalization of $51.19 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 0.88 and a beta of 0.45. argenex has a one year low of $510.05 and a one year high of $855.46.

Hedge Funds Weigh In On argenex

Several large investors have recently modified their holdings of the business. Millennium Management LLC boosted its holdings in argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after acquiring an additional 204,180 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in argenex by 114.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after acquiring an additional 158,476 shares during the period. Franklin Resources Inc. boosted its holdings in argenex by 103.9% during the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after acquiring an additional 142,606 shares during the period. BNP Paribas Financial Markets boosted its holdings in argenex by 1,203.4% during the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock valued at $78,931,000 after acquiring an additional 123,127 shares during the period. Finally, Braidwell LP boosted its holdings in argenex by 99.2% during the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock valued at $95,201,000 after acquiring an additional 80,083 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.